Life sciences companies are navigating an increasingly complex anti-corruption landscape in 2025, marked by unprecedented shifts in FCPA enforcement priorities from the DOJ and sweeping policy changes under President Trump’s Executive Orders. As enforcement expectations evolve at home, global regulators are also tightening their grip, intensifying scrutiny, demanding greater corporate accountability, and heightening international enforcement standards.
It is now more important than ever that life sciences companies act decisively to reassess risk, recalibrate priorities, refine internal controls, and fortify global compliance frameworks.
ACI’s FCPA and Anti-Corruption Conference for the Life Sciences Industry is the premier event for compliance and legal professionals to benchmark strategies, engage directly with enforcement officials, and develop proactive approaches to mitigate corruption risks worldwide.
WilmerHale Partner Amanda Masselam Strachan will speak on the panel, “Navigating the Expected Rise in Fraud & Abuse Enforcement Actions: From HHS, OIG, Anti-Kickback, False Claims and Beyond,” on May 7 at 4:00 PM ET. Topics will include:
- What recent cases and policy shifts reveal about emerging fraud and abuse trends and government priorities
- The latest initiatives from the Department of Justice, HHS-OIG, and other regulatory bodies
- How agencies are using the False Claims Act, Anti-Kickback Statute, and wire fraud laws to target fraudulent misconduct in the life sciences sector
- Proactive Compliance Strategies: steps life sciences companies should take now to strengthen internal controls, mitigate risks, and ensure regulatory alignment
